Sanofi has announced a major $294 Million Investment to expand its global Artificial Intelligence (AI) Centre of Excellence in Toronto, reinforcing its strategy to become an AI-powered biopharmaceutical leader. The expansion is expected to strengthen the company’s digital infrastructure and accelerate innovation across drug discovery, manufacturing, and healthcare operations.
The investment will create 50 New High Skilled Jobs in areas such as artificial intelligence, machine learning, data science, cloud computing, and pharmaceutical analytics by 2028. This builds on the more than 150 AI-focused roles already established since the Toronto hub was launched in 2022.
Sanofi stated that the expanded AI hub will focus on designing and deploying advanced AI tools across its global operations, helping speed up the development and delivery of medicines and vaccines. The company plans to leverage AI for areas including Drug Discovery, Predictive Modeling, Manufacturing Optimization, Regulatory Workflows, And Commercial Operations.
The project is being supported by the Invest Ontario Fund, which will contribute a conditional grant of up to $5 million as part of Ontario’s broader strategy to strengthen its life sciences and AI ecosystem. Provincial officials highlighted that the expansion reinforces Ontario’s position as a global hub for healthcare innovation and digital technologies.
Sanofi selected Toronto for its AI Centre of Excellence due to the city’s strong concentration of AI talent, research institutions, and life sciences infrastructure. The company has continued to expand its Canadian footprint in recent years, including the launch of one of Canada’s largest vaccine biomanufacturing facilities in North York.
Industry analysts believe the move reflects a broader transformation in the pharmaceutical sector, where major companies are increasingly integrating AI into core operations to improve efficiency, reduce drug development timelines, and accelerate precision medicine initiatives. Competitors including Novo Nordisk, Eli Lilly, Roche, and Merck have also intensified AI investments in recent years.
Experts note that AI is rapidly becoming central to biopharma innovation, particularly in analyzing massive biological datasets, identifying drug targets, optimizing clinical trials, and improving manufacturing quality control. Sanofi’s investment signals a long term commitment to embedding AI deeply into the future of healthcare and pharmaceutical R&D.
“With local biopharma expertise and a world class AI talent pool in Toronto, we are developing made in Canada solutions that are being scaled globally.”
By
HB Team
